Skip to main content

Epic’s Late Entry into AI Scribes Signals a Shift in EHR Strategy

August 11, 2025
Image: [image credit]
Photo 130409802 | Ai © Funtap P | Dreamstime.com

Roger Baits, Contributing Editor

Epic Systems is preparing to launch its own AI-powered ambient scribe this month, marking a strategic shift that could alter competition in one of health IT’s most dynamic segments. While the Verona, Wisconsin–based electronic health record (EHR) leader manages records for more than 42 percent of U.S. hospitals, it has until now relied on outside vendors for automated note-taking. The move brings new considerations for executives balancing automation investments, clinician workflow efficiency, and vendor dependency.

From Partnership to Proprietary Control

Epic previously partnered with Nuance, owned by Microsoft, and startup Abridge, embedding their ambient scribe tools within its platform. This approach gave health systems access to AI transcription without Epic developing the capability internally. That strategy now appears to be shifting toward proprietary control.

By owning its scribe technology, Epic gains tighter oversight of clinician workflows and deeper integration with its existing EHR functions. This mirrors a broader pattern in enterprise technology, where platform providers internalize high-demand features to strengthen user retention and reduce reliance on third parties. It is consistent with Epic’s long-standing advantage of offering a tightly integrated suite of tools, often bundled at no additional cost.

Market Timing and Competitive Pressure

Epic’s move comes after rivals such as Athenahealth, Oracle, and Elation Health have already rolled out their own ambient scribe solutions. While a late entry, Epic can leverage its scale, network reach, and customer trust to gain rapid market traction.

Research from KLAS shows Epic continued to expand its market share in 2024. Even if 20 percent of Epic’s EHR users adopt the new scribe in the first year, as some industry analysts anticipate, smaller vendors could feel immediate competitive pressure.

Clinical and Operational Stakes

Ambient scribe technology can deliver significant efficiency gains. A 2024 study in The New England Journal of Medicine found that Kaiser Permanente clinicians using an AI scribe saved more than 15,700 hours in one year compared with non-users. Reducing the administrative load allows clinicians to focus more on patient interaction and complex case management.

Still, large-scale implementation poses operational challenges. Health systems will need to assess whether Epic’s scribe offers accuracy, ease of use, and specialty-specific customization comparable to established solutions. Seamless integration alone will not guarantee adoption; consistent product performance will be critical.

Cost Considerations and ROI Pressure

Ambient scribes currently cost between $100 and $400 per clinician each month. For large systems, these recurring expenses can add up quickly. Epic may seek to disrupt pricing by bundling the tool within its EHR contracts or offering lower rates to accelerate uptake. Such a strategy could squeeze standalone vendors, many of which have recently raised substantial funding. Abridge secured $300 million this year, while Ambience Healthcare raised $243 million.

Regulatory and Privacy Context

As AI becomes further embedded in clinical documentation, regulatory and privacy considerations will remain top of mind. The lack of unified federal privacy protections for consumer-generated health data stands in contrast to the longstanding safeguards of the Health Insurance Portability and Accountability Act (HIPAA). This regulatory gap leaves questions about how ambient scribes handle, store, and protect sensitive information, especially if paired with patient-facing health apps. State-by-state privacy laws add further complexity for vendors seeking nationwide deployment.

Epic’s move into proprietary AI scribing underscores a critical turning point for the EHR market. For health system executives, the decision to adopt will hinge not only on integration and price but also on whether the tool demonstrably improves clinical efficiency without compromising compliance or data security.